Skip to main content
OpenTrials

Clinical trial condition

Recurrent Primary Peritoneal Carcinoma

Explore clinical trials studying Recurrent Primary Peritoneal Carcinoma. Study availability and eligibility vary by location and protocol.

80 public trials 11 recruiting studies
Refine in advanced search Browse all conditions

Recurrent Primary Peritoneal Carcinoma trial results

Active, Not Recruiting

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

NCT05554328

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +21 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • University of South Alabama Mitchell Cancer Institute Mobile, Alabama, United States
  • Alaska Women's Cancer Care Anchorage, Alaska, United States
  • CTCA at Western Regional Medical Center Goodyear, Arizona, United States
View all 296 locations
View Trial Details
Active, Not Recruiting

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer

NCT04092270

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +43 more
Locations
  • UCHealth University of Colorado Hospital Aurora, Colorado, United States
  • Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Memorial Sloan Kettering Monmouth Middletown, New Jersey, United States
View Trial Details
Active, Not Recruiting

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT02446600

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +27 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • University of South Alabama Mitchell Cancer Institute Mobile, Alabama, United States
  • Alaska Women's Cancer Care Anchorage, Alaska, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
View all 356 locations
View Trial Details
Active, Not Recruiting

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

NCT02502266

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +29 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Alaska Women's Cancer Care Anchorage, Alaska, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • University of Arkansas for Medical Sciences Little Rock, Arkansas, United States
View all 398 locations
View Trial Details
Active, Not Recruiting

Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT02627443

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +26 more
Locations
  • Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • UCHealth University of Colorado Hospital Aurora, Colorado, United States
  • UF Health Cancer Institute - Gainesville Gainesville, Florida, United States
View all 14 locations
View Trial Details
Active, Not Recruiting

Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer

NCT04034927

Conditions
Adnexal Diseases, Fallopian Tube Diseases, Fallopian Tube Endometrioid Tumor, +23 more
Locations
  • UC Irvine Health/Chao Family Comprehensive Cancer Center Orange, California, United States
  • UCHealth University of Colorado Hospital Aurora, Colorado, United States
  • Hartford Hospital Hartford, Connecticut, United States
  • Augusta University Medical Center Augusta, Georgia, United States
View all 20 locations
View Trial Details
Active, Not Recruiting

Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT02595892

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +18 more
Locations
  • Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • UC San Diego Moores Cancer Center La Jolla, California, United States
  • UC San Diego Medical Center - Hillcrest San Diego, California, United States
View all 17 locations
View Trial Details

Related conditions